// App-Quantinova.ai

2804 : Hypomethylating Agents and Casein Kinase 2 Inhibitor Act Synergistic and Reveal Significant Anti-Leukemic Effects in Acute Lymphoblastic Leukemia Cells

Researchers

Presenter

  • Catrin Roolf

Principal Investigators

  • Anna Richter

  • Christoph Konkolefski

  • Hugo Murua Escobar

  • Christian Junghanss

  • Yascha Khodamoradi

  • Gudrun Knuebel

  • Anett Sekora

  • Jan Stenzel

  • Bernd Joachim Krause

  • Brigitte Vollmar

  • Irmela Jeremias

  • Jens P. Panse

Medical Centers

  • Research Unit Gene Vectors, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany

  • University of Rostock Medical Center, Rostock, Germany

  • Department of Medicine III - Hematology/Oncology/Palliative Care, University of Rostock Medical Center, Rostock, Germany

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • 18F-fluorodeoxyglucose

  • Cadherin 13

  • Casein Kinase II

  • Long interspersed nucleotide element-1

Drug/Treatment

  • Doxorubicin

  • Fludeoxyglucose (18F)

  • Casein

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved